News Headlines Article

AMA joins brief opposing ‘pay-for-delay’ deals
Modern Physician

The American Medical Association joined healthcare and consumer groups calling on the U.S. Supreme Court to limit the ability of drugmakers to enter agreements that keep generic competition off the market.

The Federal Trade Commission has been battling what it calls “pay-for-delay” agreements in court with limited success for several years, arguing they illegally deny consumers the benefits of competition.

The case at issue, FTC v. Watson Pharmaceuticals, is scheduled for oral arguments before the court March 25.